Copyright © 2005, European Society of Cardiology
Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure
aDepartment of Cardiovascular Genome Science, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
bSocial Life Science, Nagoya University Graduate School of Medicine, Nagoya, Japan
cDepartment of Human Functional Genomics, Life Science Research Center, Mie University, Tsu, Japan
dDepartment of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan
eDepartment of Environmental and Molecular Medicine, Mie University School of Medicine, Tsu, Japan
* Corresponding author. Tel.: +81 52 744 2609; fax: +81 52 744 2977. Email address: myokota{at}med.nagoya-u.ac.jp
Objectives: Oxidative stress is implicated in the pathogenesis of heart failure and affects the activity of matrix metalloproteinases (MMPs). We have now investigated the role of MMPs and their tissue inhibitors (TIMPs) in the transition from compensated left ventricular (LV) hypertrophy to heart failure as well as the effects of pravastatin on this transition in a rat model.
Methods: Dahl salt-sensitive rats were fed a high-salt (8% NaCl) diet and treated with pravastatin (50 or 100 mg/kg per day) or vehicle from 7 weeks of age.
Results: Pravastatin did not attenuate LV hypertrophy apparent at 12 or 18 weeks of age. However, the high dose of this drug markedly improved indices of diastolic function (early diastolic myocardial velocity) and systolic function (LV fractional shortening) at 18 weeks of age and increased the survival rate. It also prevented a decrease in the ratio of reduced to oxidized glutathione and an increase in NADPH oxidase activity in the left ventricle induced by the high-salt diet. The activities of MMP2 and MMP9 and the abundance of TIMP1 and TIMP2 in LV tissue were increased at 18 weeks of age, and pravastatin also prevented these changes.
Conclusion: Although pravastatin did not attenuate LV hypertrophy, it prevented the transition from compensated hypertrophy to heart failure in this rat model. This effect of pravastatin may result from a reduction both in the level of oxidative stress and in MMP activity in the heart.
KEYWORDS Heart failure; Matrix metalloproteinases; NAD(P)H-oxidase; Oxidative stress; Statins
Time for primary review 34 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-A Chang, Y.-J. Kim, H.-W. Lee, D.-H. Kim, H.-K. Kim, H.-J. Chang, D.-W. Sohn, B.-H. Oh, and Y.-B. Park Effect of Rosuvastatin on Cardiac Remodeling, Function, and Progression to Heart Failure in Hypertensive Heart With Established Left Ventricular Hypertrophy Hypertension, September 1, 2009; 54(3): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schafer, P. Ellinghaus, W. Janssen, F. Kramer, K. Lustig, H. Milting, R. Kast, and M. Klein Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling Cardiovasc Res, April 1, 2009; 82(1): 30 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang, W. Tong, R. W. Troughton, M. G. Martin, K. Shrestha, A. Borowski, S. Jasper, S. L. Hazen, and A. L. Klein Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2364 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagata, K. Obata, J. Xu, S. Ichihara, A. Noda, H. Kimata, T. Kato, H. Izawa, T. Murohara, and M. Yokota Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats Hypertension, April 1, 2006; 47(4): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Newby, M. Pauschinger, and F. G. Spinale From tadpole tails to transgenic mice: Metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease Cardiovasc Res, February 15, 2006; 69(3): 559 - 561. [Full Text] [PDF]
|
|